In the current issue of Lupus, Liu et al. report ''The prognosis of pulmonary arterial hypertension (PAH) associated with primary Sjo¨gren's syndrome (pSS): a cohort study.'' 1 The mean age of onset of PAH diagnosed by right heart catheterization was soon after the recognition of pSS in patients at mean age 34 years. They excluded patients with pneumonitis or prior pulmonary emboli that may also have an associated PAH. Perhaps the most important take-home point for western rheumatologists is that this report emphasizes that the connective tissue diseases (CTDs) most associated with PAH in Asian patients were Sjogren's syndrome (pSS) or systemic lupus erythematosus (SLE). The frequency of PAH with pSS or SLE was significantly higher than in Asian patients with progressive systemic sclerosis (SSc).
This report extends an initial study by the same group 1 published in a Chinese journal that also reports the most commonly associated CTD as pSS or SLE. A study of PAH in CTD patients was previously published in Chest, which showed that among 129 consecutive Chinese adult patients with CTD associated with PAH, 49% had SLE or pSS. In comparison, only 6% had associated SSc. 2 However, these journals are not commonly read by rheumatologists.
Also, Shirai et al. reported a higher association of PAH with mixed CTD (MCTD) and SLE in Japanese patients than with SSc, 3 comprising 43% and 29% respectively. In comparison SSc was less common (19%). The most common autoantibody was anti-U1 RNA in the MCTD and SLE groups.
In a Korean registry of CTD patients with PAH, 61 had SLE, 50 had SSc and 10 had MCTD. 4 In a separate report from Korea, the CTDs associated with PAH were SLE (35%) and SSc (28%). 5 This difference in CTD association with PAH may be due to genetic or environmental factors, or a combination of both.
Recently, particular mutations in patients with idiopathic PAH have involved genes associated with bone morphogenetic protein receptor (BMPR2) and the activin A receptor (ACVRLA). 6 It is not yet known if these mutations are linked with CTD-associated PAH in either Caucasian or Chinese CTD patients.
Although we now see a significant number of American born individuals of Asian descent or those Asians who have emigrated to the USA with SLE or pSS, we have not yet identified a high incidence of PAH. 7 With ''large data'' sets now being developed, we can more easily identify whether the association with PAH is found with pSS or SLE in Chinese or other Asian patients living in the USA or Europe.
However, it is worth asking if particular environmental factors are triggering PAH in Chinese pSS and SLE patients. Conversely, we must ask if the same or different environmental factors are triggering PAH in Caucasian SSc patients.
In summary, the recent report by Lin et al. extends prior reports from Asia that PAH has a different disease association in Asian countries than is seen in the USA or Europe. 8 They studied 29 patients with pSS between 2007 and 2015.
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